(Q36731440)

15 August 2017

1 reference

title

Management of tumor lysis syndrome in adults (English)

1 reference

15 August 2017

1 reference

Bertrand Coiffier

1

1 reference

PubMed ID

17288532

15 August 2017

Catherine Riouffol

series ordinal

2

1 reference

15 August 2017

1 February 2007

1 reference

Expert Review of Anticancer Therapy

15 August 2017

1 reference

15 August 2017

7

1 reference

15 August 2017

2

1 reference

15 August 2017

233-239

1 reference

Tumour lysis syndrome: new therapeutic strategies and classification

15 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.233

Optimizing management of tumor lysis syndrome in adults with hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.233

A review of clinical and laboratory findings and treatment of tumor lysis syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.233

Acute tumor lysis syndrome. A review of 37 patients with Burkitt's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.233

Recombinant urate oxidase for prevention of hyperuricemia and tumor lysis syndrome in lymphoid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.233

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.233

Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.233

RENAL COMPLICATIONS OF NEOPLASTIC DISEASE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.233

Emergencies and their management

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.233

Hyperphosphatemia, Hyperphosphaturia and Hypocalcemia in Acute Lymphoblastic Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.233

Recent advances in pediatric acute lymphoblastic and myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.233

Tumor lysis syndrome (TLS) following fludarabine therapy for chronic lymphocytic leukemia (CLL): case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.233

Management of acute tumor lysis syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.233

Tumor lysis syndrome after bortezomib therapy for plasma cell leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.233

Oncologic emergencies in the patient with lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.233

Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.233

Urate-oxidase in the prevention and treatment of metabolic complications in patients with B-cell lymphoma and leukemia, treated in the Société Française d'Oncologie Pédiatrique LMB89 protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.233

Tumor lysis syndrome: pathogenesis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.233

PREVENTION OF HYPERURICEMIA IN LEUKEMIA AND LYMPHOMA: USE OF ALOPURINOL, A XANTHINE OXIDASE INHIBITOR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.233

A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.233

De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.233

Molecular evolution of the urate oxidase-encoding gene in hominoid primates: nonsense mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.233

Modification of uricaemia and the excretion of uric acid nitrogen by an enzyme of fungal origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.233

European experience in the treatment of hyperuricemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.233

Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.233

Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.233

Successful treatment of hyperuricemia with low doses of recombinant urate oxidase in four patients with hematologic malignancy and tumor lysis syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.233

Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.233

Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.233

Reduced-dose rasburicase in the treatment of adults with hyperuricemia associated with malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.233

A single dose of rasburicase is sufficient for the treatment of hyperuricemia in patients receiving chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.233

Recombinant urate oxidase (rasburicase) for the prevention and treatment of tumor lysis syndrome in patients with hematologic malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.2.233

21 January 2018

Identifiers

DOI

10.1586/14737140.7.2.233

1 reference

15 August 2017

1 reference

PubMed ID

17288532